Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

3DMed Completes $225 Million Round for Immunotherapy Candidates

publication date: Oct 19, 2020

3D Medicines, a Beijing clinical-stage biopharma, completed a $225 million funding. Two years ago, 3DMed spun off its diagnostics business into 3D Diagnostics and now concentrates on development of immunotherapy drugs. In 2017, 3DMed agreed to conduct the clinical trials and commercialization of Alphamab's envafolimab (KN035), a subcutaneous injection PD-L1 checkpoint inhibitor. The candidate has started clinical trials in China, the US and Japan.  The company's funding was co-led by China Capital Management and Efung Capital, a biomedical venture capital firm. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital